TNSN04079A1 - Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant - Google Patents

Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Info

Publication number
TNSN04079A1
TNSN04079A1 TNP2004000079A TNSN04079A TNSN04079A1 TN SN04079 A1 TNSN04079 A1 TN SN04079A1 TN P2004000079 A TNP2004000079 A TN P2004000079A TN SN04079 A TNSN04079 A TN SN04079A TN SN04079 A1 TNSN04079 A1 TN SN04079A1
Authority
TN
Tunisia
Prior art keywords
same
rimonabant
pharmaceutical compositions
compositions containing
preparing
Prior art date
Application number
TNP2004000079A
Other languages
English (en)
Inventor
Anne-Archardgilles
Corinne Gavory
Olivier Monnier
Alain Alcade
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of TNSN04079A1 publication Critical patent/TNSN04079A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE UN NOUVEAU POLYMORPHE CRISTALIN DU RIMONABANT; SON MODE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES CONTENANT CE NOUVEAU POLYMORPHE.
TNP2004000079A 2001-11-08 2004-05-07 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant TNSN04079A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0114579A FR2831883B1 (fr) 2001-11-08 2001-11-08 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
PCT/FR2002/003765 WO2003040105A1 (fr) 2001-11-08 2002-11-04 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
TNSN04079A1 true TNSN04079A1 (fr) 2006-06-01

Family

ID=8869285

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000079A TNSN04079A1 (fr) 2001-11-08 2004-05-07 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Country Status (33)

Country Link
US (2) US20050043356A1 (fr)
EP (1) EP1446384A1 (fr)
JP (2) JP4181994B2 (fr)
KR (2) KR20090089485A (fr)
CN (1) CN100412063C (fr)
AP (1) AP1830A (fr)
AR (1) AR037253A1 (fr)
AU (1) AU2002350869B2 (fr)
BR (1) BR0213931A (fr)
CA (1) CA2464145A1 (fr)
CO (1) CO5580827A2 (fr)
CR (1) CR7333A (fr)
EA (1) EA006771B1 (fr)
EC (1) ECSP045088A (fr)
FR (1) FR2831883B1 (fr)
GE (1) GEP20063894B (fr)
HR (1) HRP20040403A2 (fr)
HU (1) HUP0402043A3 (fr)
IL (2) IL161533A0 (fr)
IS (1) IS7226A (fr)
MA (1) MA27080A1 (fr)
ME (1) MEP21908A (fr)
MX (1) MXPA04004394A (fr)
NO (1) NO326648B1 (fr)
NZ (1) NZ532369A (fr)
OA (1) OA12721A (fr)
PL (1) PL369372A1 (fr)
RS (1) RS36904A (fr)
TN (1) TNSN04079A1 (fr)
TW (1) TW200302824A (fr)
UA (1) UA76776C2 (fr)
WO (1) WO2003040105A1 (fr)
ZA (1) ZA200402999B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1816125A1 (fr) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Formes cristallines d'un antagoniste du récepteur cannabinoïde CB1 et son procédé de préparation
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2008038143A2 (fr) * 2006-06-22 2008-04-03 Medichem, S.A. Nouvelles formes solides du rimonabant et procédés de synthèse pour la préparation de celles-ci
WO2008044153A2 (fr) * 2006-08-29 2008-04-17 Medichem, S.A. Procédé de synthèse amélioré de rimonabant
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
EP2061783A2 (fr) * 2006-09-11 2009-05-27 Hetero Drugs Limited Procédé amélioré pour l'obtention de rimonabant
WO2008035023A1 (fr) * 2006-09-19 2008-03-27 Cipla Limited Formes polymorphes de rimonabant
WO2008056377A2 (fr) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Nouvelles formes du rimonabant
WO2008064615A2 (fr) * 2006-12-01 2008-06-05 Zentiva, A.S. Formes cristallines et amorphes du rimonabant et procédés permettant d'obtenir ces formes
JP5437812B2 (ja) * 2006-12-18 2014-03-12 ７ティーエム ファーマ エイ／エス Ｃｂ１受容体モジュレーター
WO2008081208A1 (fr) 2007-01-04 2008-07-10 Prosidion Limited Agonistes de gpcr pipéridiniques
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
BRPI0806498A2 (pt) 2007-01-04 2014-04-22 Prosidion Ltd Agonistas gpcr piperidina
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
EP1944297A1 (fr) * 2007-01-09 2008-07-16 Miklós Vértessy Rimonabant solide et cristallin et procédés de préparation, ainsi que composition pharmaceutique correspondante
WO2008088900A2 (fr) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Formes polymorphes d'une base de rimonabant et procédés pour leur préparation
EP1953144A1 (fr) * 2007-01-30 2008-08-06 Sandoz AG Nouvelles formes polymorphes de N-pipéridino-5-(4-chlorophényl)-1-(2, 4-dichlorphényl)-4-méthyl-3-pyrazolecarboxamide
FR2919862A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919867A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
FR2919864A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919863A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919865A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009153804A1 (fr) * 2008-06-16 2009-12-23 Cadila Healthcare Limited Procédé de préparation de la forme 1 du rimonabant
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
CN114555557A (zh) * 2019-10-16 2022-05-27 大塚制药株式会社 森塔纳法啶的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
AU2002331595A1 (en) * 2001-08-15 2003-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Novel vasoconstrictor cannabinoid analogs
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
IS7226A (is) 2004-04-19
AP1830A (en) 2008-02-22
KR20090089485A (ko) 2009-08-21
MEP21908A (en) 2010-06-10
CN1582278A (zh) 2005-02-16
JP2005508383A (ja) 2005-03-31
MXPA04004394A (es) 2004-08-11
HRP20040403A2 (en) 2004-08-31
HUP0402043A3 (en) 2009-07-28
ECSP045088A (es) 2004-06-28
EA200400491A1 (ru) 2004-12-30
CN100412063C (zh) 2008-08-20
OA12721A (fr) 2006-06-27
GEP20063894B (en) 2006-08-10
EA006771B1 (ru) 2006-04-28
ZA200402999B (en) 2005-04-20
PL369372A1 (en) 2005-04-18
BR0213931A (pt) 2004-09-08
NZ532369A (en) 2005-10-28
TW200302824A (en) 2003-08-16
NO20041879D0 (no) 2004-05-07
IL161533A0 (en) 2004-09-27
US20050043356A1 (en) 2005-02-24
KR20050043774A (ko) 2005-05-11
NO20041879L (no) 2004-06-08
UA76776C2 (uk) 2006-09-15
NO326648B1 (no) 2009-01-26
JP4931874B2 (ja) 2012-05-16
CO5580827A2 (es) 2005-11-30
CA2464145A1 (fr) 2003-05-15
HUP0402043A2 (hu) 2005-01-28
WO2003040105A1 (fr) 2003-05-15
RS36904A (en) 2006-10-27
JP2009035547A (ja) 2009-02-19
MA27080A1 (fr) 2004-12-20
CR7333A (es) 2008-09-23
EP1446384A1 (fr) 2004-08-18
AU2002350869B2 (en) 2007-07-26
AR037253A1 (es) 2004-11-03
FR2831883A1 (fr) 2003-05-09
IL161533A (en) 2010-05-31
US20100190827A1 (en) 2010-07-29
JP4181994B2 (ja) 2008-11-19
FR2831883B1 (fr) 2004-07-23
AP2004003024A0 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
TNSN04079A1 (fr) Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
HUP0302519A2 (hu) Az atorvasztatin kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA02012795A (es) Carvedilol.
MY148297A (en) Process for modifying drug crystal formation
PT915898E (pt) Forma i cristalina de claritromicina
IL172331A (en) Process for Preparation of Compound 8-Hello-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazapine, Intermediate Compound, Method for Separating Mixture of Compound , Preparation and use of hydrochloric acid salt in drug production
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
DE69229339T2 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
ATE430160T1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
HUP0301862A3 (en) Lactam compound, pharmaceutical composition containing it, process for producing it, intermediates and use of it for producing pharmaceutical composition
ATE401332T1 (de) Neue polymorphe von olanzapin-hydrochlorid
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
DE69920708D1 (de) Verfahren zur herstellung von 1,4-bis[[2-(dimethylamino)ethyl amino]-5,8-dihydroxyanthracene-9,10-dion
HUP0402553A2 (hu) Venlafaxin-hidroklorid-monohidrát, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
DE50208851D1 (de) Gelierzucker und verfahren zu dessen herstellung
ATE325794T1 (de) Verfahren zur herstellung und zwischenprodukte von pyridin-2-yl-amin
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
ATE421961T1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
ATE339423T1 (de) Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
PT1259507E (pt) Forma pseudopolimorfica de (-)-cis-2-(2-clorofenil)-5,7-di-hidroxi-8[4r(3s-hidroxi-1-metil)piperidinil]-4h-benzopiran-4-ona
ATE299147T1 (de) Verfahren zur herstellung von 3-amino-1,5- benzodiazepinderivaten